Trial · NCT04413617
Adverse events85
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 85
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Tofacitinib 11mg MR | 4 | 102 | |
| other | Nausea | Gastrointestinal disorders | PF-06651600 100mg | 5 | 77 | |
| other | Nausea | Gastrointestinal disorders | PF-06650833 400mg MR | 2 | 77 | |
| other | Nausea | Gastrointestinal disorders | PF-06650833 400mg MR + Tofacitinib 11mg MR | 1 | 103 | |
| other | Nausea | Gastrointestinal disorders | PF-06650833 400mg MR + PF-06651600 100mg | 3 | 101 | |
| other | Nasopharyngitis | Infections and infestations | Tofacitinib 11mg MR | 3 | 102 | |
| other | Nasopharyngitis | Infections and infestations | PF-06651600 100mg | 2 | 77 | |
| other | Nasopharyngitis | Infections and infestations | PF-06650833 400mg MR | 1 | 77 | |
| other | Nasopharyngitis | Infections and infestations | PF-06650833 400mg MR + Tofacitinib 11mg MR | 3 | 103 | |
| other | Nasopharyngitis | Infections and infestations | PF-06650833 400mg MR + PF-06651600 100mg | 6 | 101 | |
| other | Urinary tract infection | Infections and infestations | Tofacitinib 11mg MR | 5 | 102 | |
| other | Urinary tract infection | Infections and infestations | PF-06651600 100mg | 1 | 77 | |
| other | Urinary tract infection | Infections and infestations | PF-06650833 400mg MR | 1 | 77 | |
| other | Urinary tract infection | Infections and infestations | PF-06650833 400mg MR + Tofacitinib 11mg MR | 7 | 103 | |
| other | Urinary tract infection | Infections and infestations | PF-06650833 400mg MR + PF-06651600 100mg | 3 | 101 | |
| other | SARS-CoV-2 test positive | Investigations | Tofacitinib 11mg MR | 7 | 102 | |
| other | SARS-CoV-2 test positive | Investigations | PF-06651600 100mg | 1 | 77 | |
| other | SARS-CoV-2 test positive | Investigations | PF-06650833 400mg MR | 2 | 77 | |
| other | SARS-CoV-2 test positive | Investigations | PF-06650833 400mg MR + Tofacitinib 11mg MR | 4 | 103 | |
| other | SARS-CoV-2 test positive | Investigations | PF-06650833 400mg MR + PF-06651600 100mg | 8 | 101 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04413617/events